If 2015 was a dream year for Wall Street’s top dealmakers, 2016 is starting to take a nightmarish turn. Some of the mega transactions that had champagne corks popping in boardrooms are running into antitrust problems and, in the case of pharmaceutical firm Pfizer Inc’s (PFE.N) $160 billion takeover of ... Read More »